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1. Introduction 
Apolipoprotein E from human plasma lipoproteins 
exhibits a genetic polymorphism that is under the 
control of two allelic autosomal genes designated 
Ape En and Ape Ed. These alleles determine the three 
phenotypes Apo E-N, Apo E-ND and Apo E-D [ 1,2]. 
The Apo E-ND polymorphism possibly is of high 
biological significance, Both the mean plasma choles- 
terol levels and the distribution of cholesterol among 
the lipoprotein classes are different in the three pheno- 
typic groups [3]. 
The Apo E-phenotypes are demonstrated by iso- 
electric focusing and are defied by the ratio of the 
polymorphic forms Apo E-II/APO E-III [ 1,4]. In the 
phenotype Apo E-D the Apo E-III form is deficient. 
Individuals with Apo E-III deficiency that represent 
about 1% of the German population have low plasma 
cholesterol evels and primary dysbetalipoproteinaemia 
(type III dyslipoproteinaemia) [l-3]. Coinheritance 
however of the gene Apo .I@ in double dose and genes 
for familial hyperlipidaemia results in the clinical 
disorder hyperlipoproteinaemia type III [2,5]. 
The chemical differences between the polymorphic 
forms of Apo E are not yet known, We show here 
that apolipoproteins E from phenotypes Apo E-N and 
Apo E-D differ in M, according to their mobility in 
SDS-PAGE and that this reflects a difference in size 
of Apo E-II and Apo E-III, that are the major Apo E 
polymorphic forms of the two phenotypes, respec- 
tively . 
Abbrevations: SDS, sodium dodecyl sulfate; PAGE, poly- 
acrylamide gel electrophoresis; IEF, isoelectric focusing 
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2. Materials and methods 
Blood was obtained from fasting individuals with 
hyperlipoproteinaemia types III, IV and V. Very low 
density lipoproteins (VLDL) were isolated at +4”C by 
centrifugation of sera at 59 000 rev./min for 20 h in 
the 60 Ti rotor of the L2-65B ultracentrifuge 
(Beckman Inst.) and purified by recentrifugation in 
0.85% NaCl-0.05% EDTA (pH 7.4). Lipids were 
extracted from VLDL by acetone-aethanol 1: 1 (v/v) 
at -20°C. Apo E was purified from apo VLDL by 
preparative SDS-PAGE in the discontinuous system 
[6] as outlined in [7]. Analytical SDS-PAGE [6] 
was performed in slab gels either at a continuousmain 
gel concentration (10% or 15% acrylamide) or in a 
linear gradient from 15-30% acrylamide. Apoproteins 
were reduced and alkylated before electrophoresis 
[8]. For radioactive labelling apo VLDL (2.5 mg) was 
solubilised in 0.5 ml 0.2 M Tris-HCl (pH 8.6) 6 M 
guanidine-HCl and reduced by addition of 620 nM 
dithioerythritol (DTE) for 60 min at 37°C and then 
reacted with 10 PCi iodo-[ 1 -i4C]acetamide (Amersham 
Buchler, spec. act. 57 mCi/mmol) for 30 min at room 
temperature in the dark. A 3-fold molar excess over 
DTE of cold iodo-acetamide (0.37 mg) were then 
added and the reaction continued for a further 
30 min period. Alkylation was stopped by addition 
of 2-mercaptoaethanol to 5% final cont. The sample 
was dialysed against Hz0 and lyophilised. 
The polymorphic forms of Apo E were isolated 
by preparative IEF in the presence of 6 M urea, in 
granulated gels [9] containing a 2: 1 (v/v) mixture of 
ampholines (pH 4-6; pH 5-7) (LKB productor, 
Bromma). Reduced Apo E was focused for 18 h at 
21 
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20 W using the LKB multiphor equipment. Protein 
zones were detected by a paper print technique [9]. 
The pI values were determined in aliquots of the gel 
diluted in Hz0 with a pH electrode. Ampholines were 
removed from protein by chromatography on Sephadex 
G-50. Analytical IEF was performed in polyacryl- 
amide gels in a gradient of pH 3.5-10 as outlined 
[ 1,4]. Reduced and alkylated proteins were dialysed 
extensively against 0.02 M aethylmorpholine-HCI 
(pH 8.6) before focusing. CNBr fragmentation of 
0.2-l .O mg Apo E in 70% HCOOH was performed 
for 24 h at room temperature with a 400-fold molar 
excess of CNBr. CNBr peptides were analysed on 
polyacrylamide gel gradients as outlined [lo]. 
For neuraminidase treatment 300 pg apo VLDL 
was solubilised in 300 ~1 0.05 M Na-acetate, 0.068 M 
CaCl*, 0.154 M NaCl (pH 5.5). The buffer was either 
1 mM in SDS or 0.5 mM in Triton X-l 00. Neuraminid- 
ase (V. choZerae, 500 u/ml, Behringwerke, Marburg) 
30 ~1, was added and the mixture incubated for 20 h 
at 37°C. Controls were incubated without neuraminid- 
ase. Samples were dialysed against 0.02 M aethyl- 
morpholineeHC1 (pH 8.6). Then 300 ~1 of 12 M 
urea in Hz0 were added and 200 ~1 aliquots were 
subjected to IEF. 
3. Results and discussion 
The polymorphism of Apo E demonstrated by 
IEF might be a result of different degrees of sialyla- 
tion of the Apo E protein. Therefore apo VLDL was 
treated with neuraminidase in the presence of deter- 
gent (Triton X-100 and SDS) and the Apo E patterns 
were analysed by IEF. No changes in the focusing 
properties of the Apo E bands were observed (tig.1). 
The polymorphic forms of Apo C-III in VLDL 
however that are known to contain 2 (Apo C-111-2) 
and 1 (Apo C-111-1) mol sialic acid/m01 protein [ 11,121 
were almost quantitatively converted to the asialo- 
protein (C-III-O). This strongly suggests that sialic acid 
is not responsible for the Apo E polymorphism. 
Reduced and alkylated samples of apo VLDL 
from individuals of phenotypes Apo E-N, Apo E-ND 
and Apo E-D were subjected to SDS-PAGE. This 
demonstrated a slower mobility of the major Apo E 
component from phenotype Apo E-D compared to 
Apo E-N. The heterozygous phenotype Apo E-ND 
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Fig.1. Isoelectric focusing in PAGE of control apo VLDL (a) 
and neuraminidase treated apo VLDL (b) of phenotype 
Apo E-ND in a gradient of pH 3.5 -10. Apo VLDL was treated 
with neuraminidase in the presence of SDS or Triton X-100 
(right). Numbers label apolipoprotein C-HI-2 (l), C-III-1 (2), 
C-III-O (3) and apo E (4). Arrow indicates an unidentified 
apolipoprotein affected by the neuraminidase treatment. 
exhibited two clearly separated Apo E bands (fig.2). 
SDS-PAGE in a gradient gel from 15-30% acryl- 
amide confirmed this finding (fig.3). This indicated 
that Apo E from phenotypes Apo E-N and Apo E-D 
is of different molecular size. Apo E-N was M, 
-33 000 and Apo E-D Mr -34 500. 
In IEF Apo E-III is the major constituent of 
Apo E-N and Apo E-II is the main constituent of 
Apo E-D. This suggests that the different mobilities 
of Apo E in SDS-PAGE reflect size differences in 
the Apo E-III and Apo E-II forms of the protein. 
These forms as well as Apo E-I were partially puri- 
fied by preparative IEF in granulated gels (not shown). 
SDS-PAGE of the reduced and alkylated apoproteins 
shows that Apo E-II and Apo E-III in fact have dif- 
ferent mobilities (fig.2) and that the Apo E-I protein 
has the lowest mobility. This difference in mobilities 
cannot be explained by the charge differences of the 
proteins, since according to charge Apo E-II should 
be of higher mobility than Apo E-III. Also anomalous 
binding of SDS by one of the proteins seems unlikely 
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Fig.2. SDS-PAGE in 15% acryiamide gels (A) and 10% acrylamide gels (Bf of apo VLDL and Apo E preparations, (A) ape VLDL 
of phenotypes Apo E-N [IJ], Apo E-ND [3] and Apo E-D [4,5]. (B) apo VLDL of phenotypes Apo E-D [I], Apo E-ND [6] and 
Apo E-N [S ] and of Apo E-I [ 21, APO E-II + E-III [3 ] and Apo E-III [ 4 1. In the 10% gels Apo C has run out of the gels. 
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Fig.3. SDS-PAGE of apo VLDL (phenotype Apo E-ND) in a gel gradient from 15-30% acrylamide concentration. Apo VLDL 
was reduced with DTE and alkylated with iodo-[ l-‘4C]acetamide. The Coomassie brilliant blue-stained gel and the evaluation by 
scanning densitometry is shown. In the insert the distribution of “‘C radioactivity in the same gel is shown. 
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Table 1 
Distribution of Apo E-proteins in unreduced and reduced and alkylated 
apo VLDL (% densitometric area) 
Apoprotein Phenotype 
Apo E-N Apo E-ND Apo E-D 
unred. red. unred. red. unred. red. 
E-I 29 16 43 31 49 30 
E-II 25 25 30.5 35.5 51 59 
E-III 46 59 26.5 33.5 7 11 
unred., unreduced; red., reduced and alkylated 
in view of the similarities of the primary structure of 
the proteins (see below). 
Apoprotein E does contain cysteine [ 131 and does 
form complexes with Apo A-II by disulfide bridge 
formation [ 141. Also the quantitative distribution of 
Apo E isoproteins in IEF is affected by reduction and 
alkylation (table 1) indicating inter- and/or intrachain 
disulfide bridge formation. In unreduced apo VLDL 
comparatively more protein does focus in the position 
of Apo E-I and in a position of minor bands anodic 
of Apo E-I. 
To ensure complete reduction of the protein and 
also to determine whether the Apo E polymorphic 
forms differ in cysteine content apo VLDL from the 
heterozygous phenotype Apo E-ND was reduced with 
DTE and alkylated with iodo-[ 14C Jacetamide. 
After SDS-PAGE and IEF of aliquots the stained 
gels were evaluated by scanning densitometry. They 
were then sliced and analysed for radioactivity. Apo B 
(in SDS-PAGE) and Apo E were heavily labelled 
whereas no 14C radioactivity was recovered from the 
Apo C proteins, that are known to contain no cysteine 
[ 111. Hence there is little, if any, unspecific labelling 
of the proteins under our experimental conditions. 
The distribution of 14C radioactivity in the Apo E 
bands from SDS-PAGE corresponds closely to the 
distribution of protein from scanning densitometry. 
The data from SDS-PAGE also agree well with those 
obtained from the IEF gels (table 2). The experiment 
thus shows that Apo E is in a reduced state in both 
systems and that the Apo E forms probably contain 
the same number of cysteine residues per chain. 
The polymorphic nature of human Apo E has been 
demonstrated [l-5,7,1 51. There was however no 
direct evidence showing that the Apo E bands detected 
by IEF are indeed polymorphic forms of one protein 
rather than representing nonidentical polypeptide 
chains. Crossed immunoelectrofocusing of apo VLDL 
against a monospecific anti-APO E serum (raised 
against total Apo E) demonstrated a reaction of com- 
plete immunological identity of the Apo E focusing 
bands (fig.4). This was confirmed by double diffusion 
experiments of the isolated Apo E bands (not shown). 
CNBr fragments were prepared from purified 
Apo E of phenotype Apo E-N (predominantly Apo 
E-III) and phenotype Apo E-D (predominantly Apo 
Table 2 
Distribution of reduced and alkylated Apo E-proteins in phenotype Apo E-ND 
Apoprotein IEF SDS-PAGE 
Densitometric 14C radioactiv- Densitometric 14C radioactiv- 
area (%) ity (%) area (%) ity (%) 
E-I 31.0 29.5 
E-II 41.0 I 72.0 43.6 73.1 70.5 68.6 
E-III 28.0 26.9 29.5 31.4 
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Fig.4. Crossed immunoelectrofocusing of urea soluble apo 
VLDL (phenotype Apo E-ND) against anti-Apo E. Focusing 
was performed in a gradient of pH 3.5-6. Staining: Coomassie 
brilliant blue. E-I’ labels a minor band (p1 -5.2) anodic of 
Apo E-I. 
E-II, ‘rig.2) and the resulting peptides were analysed 
by SDS-PAGE gradient electrophoresis (fig.5). The 
peptide patterns from both proteins were indis- 
tinguishable and exhibited a major band of M, 
-11 500. This confirms the structural similarities 
of the Apo E-II and Apo E-III forms. The difference 
in the Mr of the intact proteins thus is not reflected 
in the peptide pattern. This however possibly is due 
to the poor staining and resolution of the smaller pep- 
tides in the electrophoretic system used. 
It is not yet clear by what mechanism the deficiency 
of the E-III protein does result in the dysbetalipo- 
proteinaemia. In normal individuals VLDLis degraded 
in a continous process to lipoproteins of intermediate 
density (IDL or remnants) and finally to LDL (CQ- 
pathway, [16]). The typical dyslipoproteinaemia in 
individuals of phenotype Apo E-D is best explained 
assuming a metabolic block in the cwz-pathway at the 
IDL + LDL interconversion step. The finding that also 
heterozygous individuals (phenotype Apo E-ND) that 
contain relatively less Apo E-III in VLDL particles 
than the usual phenotype Apo E-N, tend to a mild 
form of dysbetalipoproteinaemia [3] suggests that the 
number of Apo E-III copies/particle is critical for the 
catabolism of VLDL. The slightly but definitely 
higher M, of the E-II form in connection with the 
quantitative character of the Apo E-ND polymorphism 
might then indicate that Apo E-II is an inactive pre- 
cursor that is only partially converted to the active 
E-III form in phenotype Apo E-ND and not at all in 
phenotype Apo E-D. 
In summary our data show that the Apo E bands 
A6 c 6 E 
Fig.5. SDS-polyacrylamide gel gradient electrophoresis of 
CNBr peptides from Apo E of phenotypes Apo E-N (C) 
and Apo E-D (D): A, HSA; B, CNBr peptides from HSA; E, 
Apo E. Numbers label fragments ofMr -16 500 (1), 
-12 500 (2), -11 500 (3), -8000 (4) and -6000 (5). 
separated by IEF are structurally closely related and 
represent polymorphic forms of one protein. There 
does however exist a difference in the Mr of the Apo 
E-I, Apo E-II and E-III proteins. 
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